|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 11,806,321: Ritodrine Hydrochloride Formulations
U.S. Patent 11,806,321, granted on October 31, 2023, to Aspen Holdings, Inc., claims novel crystalline forms of ritodrine hydrochloride and methods for their preparation. These forms are characterized by specific X-ray powder diffraction (XRPD) patterns, differential scanning calorimetry (DSC) profiles, and infrared (IR) spectroscopy data, aiming to provide improved stability and therapeutic efficacy. The patent addresses limitations in existing ritodrine hydrochloride formulations, particularly concerning polymorphic impurities and degradation.
What is the Core Invention of U.S. Patent 11,806,321?
The patent's central innovation lies in the identification and characterization of specific crystalline forms, or polymorphs, of ritodrine hydrochloride. These polymorphs are designated as Form A and Form B.
- Form A: Characterized by a powder X-ray diffraction pattern exhibiting specific peaks at approximately 8.1, 12.2, 13.8, 15.0, 16.2, 18.0, 20.5, 22.6, 24.2, 25.2, 27.8, and 30.0 degrees 2-theta (± 0.2 degrees 2-theta). Its differential scanning calorimetry (DSC) profile shows an endotherm with a peak temperature of approximately 162°C (± 2°C).
- Form B: Characterized by a powder X-ray diffraction pattern exhibiting specific peaks at approximately 7.6, 10.1, 14.5, 16.0, 19.1, 20.0, 22.1, 24.5, 26.9, and 30.4 degrees 2-theta (± 0.2 degrees 2-theta). Its DSC profile shows an endotherm with a peak temperature of approximately 172°C (± 2°C).
The patent asserts that these specific crystalline forms offer enhanced stability compared to previously known forms, reducing the propensity for degradation and the formation of unwanted impurities. This is critical for ritodrine hydrochloride, an adrenergic beta-2 receptor agonist used to prevent premature labor.
What are the Key Claims within the Patent?
U.S. Patent 11,806,321 contains multiple independent and dependent claims detailing the invention. The primary claims focus on the specific crystalline forms and their preparation.
- Claim 1: Claims an isolated crystalline form of ritodrine hydrochloride, designated as Form A, characterized by its XRPD pattern.
- Claim 2: Claims an isolated crystalline form of ritodrine hydrochloride, designated as Form B, characterized by its XRPD pattern.
- Claim 3: Claims Form A as further characterized by its DSC profile with a specific endotherm peak.
- Claim 4: Claims Form B as further characterized by its DSC profile with a specific endotherm peak.
- Claim 5: Claims a method for preparing Form A, involving specific crystallization conditions.
- Claim 6: Claims a method for preparing Form B, involving specific crystallization conditions.
- Claim 7: Claims a pharmaceutical composition comprising Form A and a pharmaceutically acceptable carrier.
- Claim 8: Claims a pharmaceutical composition comprising Form B and a pharmaceutically acceptable carrier.
- Claim 9: Claims a method for treating preterm labor, comprising administering an effective amount of a pharmaceutical composition of Form A or Form B.
Dependent claims further refine these aspects, specifying purity levels, particle size, and combinations of characterization data. For instance, claims may further define Form A by its IR spectrum or specific combinations of XRPD peaks.
What are the Asserted Advantages of the Patented Forms?
The patent emphasizes several advantages over existing ritodrine hydrochloride materials.
- Improved Stability: The identified crystalline forms (Form A and Form B) exhibit greater intrinsic stability. This translates to a longer shelf life and reduced degradation during manufacturing, storage, and administration.
- Reduced Impurity Formation: Enhanced stability directly correlates with a lower propensity for forming degradation products and related impurities. This is crucial for patient safety and regulatory compliance.
- Consistent Therapeutic Efficacy: By providing a more stable and pure active pharmaceutical ingredient (API), the patented forms are expected to deliver more consistent therapeutic outcomes. Polymorphic impurities can affect dissolution rates and bioavailability.
- Manufacturing Reproducibility: The patent outlines methods for preparing these specific polymorphs, implying that their isolation and production are reproducible on a commercial scale.
What is the Prior Art Landscape for Ritodrine Hydrochloride Polymorphs?
The patent implicitly addresses existing knowledge and formulations of ritodrine hydrochloride. Ritodrine hydrochloride has been an established drug for decades, meaning prior art likely includes patents and publications detailing its synthesis, various salt forms, and potentially other crystalline or amorphous forms.
- Existing Polymorphs: It is common for drug substances to exist in multiple crystalline forms. Older patents or scientific literature may describe other polymorphs of ritodrine hydrochloride. U.S. Patent 11,806,321 aims to differentiate its claimed forms from these prior art polymorphs through specific crystallographic and thermal data.
- Amorphous Ritodrine Hydrochloride: Amorphous forms, while sometimes offering dissolution advantages, often suffer from poor physical stability and hygroscopicity.
- Impurity Profiles: Past research and regulatory filings for ritodrine hydrochloride would have established acceptable impurity limits and identified common degradation pathways. This patent claims forms that mitigate these known issues.
A thorough prior art search would be necessary to fully assess the novelty and inventiveness of Form A and Form B. This would involve examining existing patents, scientific journals, and patent databases for any prior disclosures of these specific crystalline forms or methods for obtaining them with similar characteristics.
What is the Significance of Polymorphism for Pharmaceutical Development?
Polymorphism is a critical consideration in pharmaceutical development due to its profound impact on drug substance properties and performance.
- Physical Properties: Different polymorphs of the same compound can exhibit variations in melting point, solubility, dissolution rate, density, and hygroscopicity.
- Therapeutic Impact: These physical property differences can directly influence the bioavailability, efficacy, and safety of a drug product. For example, a less soluble polymorph might lead to reduced absorption and sub-therapeutic drug levels, while a more hygroscopic form could degrade rapidly.
- Manufacturing Challenges: The presence of multiple polymorphs can create challenges in manufacturing processes such as crystallization, drying, and milling, requiring strict control to ensure the desired form is consistently produced.
- Regulatory Scrutiny: Regulatory agencies (e.g., FDA, EMA) require stringent control over the polymorphic form of an API to ensure batch-to-batch consistency and predictable therapeutic performance. Changes in polymorphic form can necessitate new drug applications or extensive validation studies.
The claims in U.S. Patent 11,806,321, by defining specific crystalline forms with detailed characterization, aim to provide patent protection for a more stable and potentially superior solid-state form of ritodrine hydrochloride, offering a distinct advantage over existing or less stable forms.
What are the Potential Commercial Implications?
The granting of this patent has several implications for companies involved with ritodrine hydrochloride.
- Market Exclusivity: Aspen Holdings, Inc. may gain market exclusivity for formulations utilizing Form A and Form B of ritodrine hydrochloride during the patent term. This could involve manufacturing, selling, or importing products containing these specific forms.
- Licensing Opportunities: Other pharmaceutical companies may seek to license the patented technology to develop or manufacture their ritodrine hydrochloride products.
- Litigation Risk: Competitors developing or marketing ritodrine hydrochloride products that infringe on these claims could face patent infringement lawsuits.
- Development Strategy: Companies currently developing or planning to develop ritodrine hydrochloride products will need to assess whether their formulations utilize a claimed form or method, and plan accordingly to avoid infringement or seek licensing. This might involve developing non-infringing polymorphs or formulations.
- Generic Competition: For generic manufacturers, this patent represents a hurdle. They must either wait for the patent to expire or develop a non-infringing formulation, potentially using a different polymorphic form or a salt of ritodrine that is not covered by the claims.
The patent's duration is subject to adjustments for patent term adjustments and potential extensions, but it generally provides a period of exclusivity from the grant date.
Key Takeaways
- U.S. Patent 11,806,321 protects specific crystalline forms of ritodrine hydrochloride, designated Form A and Form B, with defined XRPD, DSC, and IR characteristics.
- The patent claims these forms provide improved stability and reduced impurity formation compared to prior art forms of ritodrine hydrochloride.
- Key claims cover the isolated crystalline forms, methods for their preparation, and pharmaceutical compositions containing them.
- The patent has implications for market exclusivity, licensing, and potential litigation for companies involved in ritodrine hydrochloride manufacturing and development.
- Understanding and avoiding infringement of these specific polymorphic claims is crucial for generic and innovator companies operating in this therapeutic area.
FAQs
-
What is the primary difference between Form A and Form B as claimed in U.S. Patent 11,806,321?
Form A and Form B are distinguished by their unique powder X-ray diffraction patterns and differential scanning calorimetry profiles, indicating distinct crystalline structures with different thermal properties.
-
Does U.S. Patent 11,806,321 cover all forms of ritodrine hydrochloride?
No, the patent specifically claims isolated crystalline forms designated as Form A and Form B, along with methods for their preparation and pharmaceutical compositions. It does not broadly cover all possible salt forms, hydrates, solvates, or amorphous forms of ritodrine hydrochloride.
-
How does the stability of Form A and Form B compare to other known ritodrine hydrochloride polymorphs?
The patent asserts that Form A and Form B exhibit enhanced stability, leading to reduced degradation and impurity formation. The specific comparative data against other prior art polymorphs would be detailed within the patent's specification or supporting documentation.
-
Can a generic drug manufacturer produce ritodrine hydrochloride if it uses a different crystalline form?
Yes, if a generic manufacturer can demonstrate that their product utilizes a crystalline form of ritodrine hydrochloride that is not claimed by U.S. Patent 11,806,321, or if the patent has expired, they may be able to proceed without infringement.
-
What is the therapeutic use of ritodrine hydrochloride that is relevant to this patent?
Ritodrine hydrochloride is an adrenergic beta-2 receptor agonist primarily used to prevent premature labor by relaxing the uterine smooth muscle. The improved stability of the claimed forms is intended to enhance the reliability and safety of such therapeutic applications.
Citations
[1] Aspen Holdings, Inc. (2023). Ritodrine hydrochloride crystalline forms and methods of preparation. U.S. Patent 11,806,321. Washington, D.C.: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
